Director, Head of Product Development

Responsibilities

• Lead the development and optimization of highly multiplexed molecular assays for plasma-based applications
• Translate early biological and assay signals into robust, reproducible, and clinically meaningful diagnostic outputs
• Drive improvements in assay sensitivity, specificity, multiplexing performance, and reproducibility
• Develop analytical workflows, assay QC frameworks, and validation strategies to support future clinical deployment
• Build, mentor, and manage a high-performing assay and product development team
• Partner with platform and discovery teams to prioritize and advance clinically actionable programs
• Establish the technical and operational foundation for future CLIA/LDT deployment and clinical validation

Requirements

• PhD in Molecular Biology, Bioengineering, Biochemistry, Biomedical Engineering, or a related field
• 10+ years of industry experience with significant expertise in molecular diagnostic or liquid biopsy assay development
• Proven track record of translating early-stage biological discoveries into deployable assay workflows
• Deep expertise in highly multiplexed molecular assays and qPCR or NGS-based assay readouts
• Experience developing assays intended for clinical studies, translational programs, or CLIA/LDT environments
• Demonstrated ability to improve assay reproducibility, sensitivity, and specificity in complex biological samples
• Experience building and mentoring scientific teams in high-growth biotech or diagnostics organizations

Preferred Qualifications

• Experience with proximity-based assay technologies
• Expertise in liquid biopsy and plasma-based diagnostics
• Knowledge of protein and/or RNA biomarker detection
• Experience with ultra-sensitive molecular detection platforms
• Background in extracellular vesicle biology or advanced cell-resolved diagnostics

Benefits

• Healthcare coverage
• Annual incentive program
• Retirement benefits
• Broad range of other company benefits

About the Company

Flagship Labs 103, Inc. is a privately held early-stage company developing advanced molecular technologies designed to detect highly sensitive, cell-resolved biological signals from minimally invasive biospecimens. Founded by Flagship Pioneering, FL103 aims to enable earlier disease detection, longitudinal disease monitoring, and improved patient stratification across oncology, neurodegenerative disease, and other major disease areas.